每经AI快讯，*ST金比（SZ 002762，收盘价：6.6元）8月26日晚间发布公告称，公司第五届第二十次董 事会会议于2025年8月26日在公司会议室以现场表决的方式召开。会议审议了《关于召开2025年第二次 临时股东大会的通知》等文件。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 （记者 王晓波） 2024年1至12月份，*ST金比的营业收入构成为：母婴消费品行业占比97.27%，其他占比2.73%。 截至发稿，*ST金比市值为23亿元。 ...

Core Viewpoint - The frequent changes in control of listed companies, exemplified by *ST Jinbi's abrupt termination of its control transfer, highlight regulatory scrutiny and the complexities involved in such transactions [1][5]. Group 1: Company Specifics - *ST Jinbi announced a control transfer to Shanghai Yuanyi Chengwu Technology Co., Ltd. on June 6, 2023, but this was terminated less than two months later due to regulatory issues concerning the acquirer's actual controller [2][3]. - The company, established in 1996, focuses on mid-to-high-end maternal and infant products, with brands including "LABI BABY," "I LOVE BABY," and "BABY LABI" [2]. - The proposed share transfer involved 47.085 million shares, representing 13.30% of the total share capital, at a price of 7.34 yuan per share, totaling 346 million yuan [2][3]. Group 2: Regulatory Issues - The Shenzhen Stock Exchange issued a regulatory letter to Yuanyi Chengwu and its actual controller, Chen Keru, for failing to disclose that the ultimate controlling entity, Haoran Chunhui, was under court-ordered liquidation [4]. - The control transfer was halted due to uncertainties arising from the acquirer's family asset liquidation disputes, leading to mutual agreement to terminate the transaction [3][4]. Group 3: Industry Trends - Over 75 listed companies in A-shares have announced control changes this year, with more than 10 successfully completing transfers and three, including *ST Jinbi, terminating their transactions [5]. - The trend of control changes spans various industries, including textiles, chemicals, machinery, and pharmaceuticals, with over 40% of these companies reporting losses in 2024 [5][6]. - The involvement of private equity and local state-owned enterprises in acquiring control of listed companies is notable, with several transactions completed or in progress [6].

Core Viewpoint - The control change of *ST Jinbi has been terminated, leading to a significant impact on the company's stock price and financial outlook, with a projected net loss for the first half of 2025. Group 1: Control Change Announcement - *ST Jinbi announced the termination of the control change agreement with Yuan Yi Cheng Wu Technology Co., Ltd., which was initially set to transfer 13.3% of the company's shares [1][3] - The termination was due to uncertainties arising from family asset liquidation disputes involving Yuan Yi Cheng Wu's actual controller, leading both parties to agree to halt the transaction [2][3] Group 2: Financial Performance Forecast - The company expects a revenue of approximately 160 million to 170 million yuan for the first half of 2025, representing a year-on-year growth of 104.45% to 117.23% [5] - However, the net profit is projected to be a loss of 8 million to 16 million yuan, indicating an increase in losses compared to the previous year [5] Group 3: Market Reaction and Future Plans - Following the announcement of the control change, *ST Jinbi's stock price experienced consecutive limit-ups, but the termination of the control change has raised concerns in the market [5] - The company plans to continue focusing on emerging industries to seek new growth points for performance improvement [4]

Core Viewpoint - The stock price of *ST Jinbi surged to a limit up of 6.47 yuan per share following the announcement of a change in control, with Shanghai Yuancheng Chengwu Technology Co., Ltd. becoming the new controlling shareholder and Chen Keru as the actual controller [1]. Group 1: Control Change Details - On June 11, the current controlling shareholders Lin Haoliang and Lin Ruowen signed a share transfer agreement with Yuancheng Chengwu, transferring a total of 13.3% of the company's shares at a price of 7.34 yuan per share, amounting to approximately 346 million yuan [1]. - After the first transfer, Yuancheng Chengwu will hold 13.3% of the shares and the current shareholders will relinquish their voting rights, leading to a board majority for Yuancheng Chengwu [1]. - Upon completion of the second transfer, Yuancheng Chengwu will own 28% of the shares, with the previous shareholders continuing to forfeit their voting rights [1]. Group 2: Company Performance and Risks - Founded in 1996, *ST Jinbi specializes in the research, design, production, and sales of maternal and infant consumer products, managing brands such as "LABI BABY," "I LOVE BABY," and "BABY LABI" [4]. - The company reported a total profit of 70.77 million yuan and a net profit of 49.69 million yuan for the fiscal year 2024, but the net profit after excluding non-recurring gains and losses was -45.32 million yuan, with revenue below 300 million yuan [4]. - In Q1 of the current year, the company achieved revenue of 76.06 million yuan, a year-on-year increase of 74.85%, but the net profit after deductions was -253,030 yuan, indicating a shift from profit to loss [5].

Core Viewpoint - The company *ST Jinbi is undergoing a potential change in control, with its major shareholders planning to transfer shares, which introduces both hope and uncertainty for the company's future [2][3][6] Group 1: Control Change Announcement - On June 5, *ST Jinbi announced a suspension of trading due to plans for a change in control, with the suspension expected to last no more than two trading days [2] - The change in control is currently in the negotiation stage, and there is significant uncertainty surrounding the outcome [3] Group 2: Shareholding Structure - As of the end of Q1 2025, the major shareholders Lin Haoliang and Lin Ruowen hold 27.29% and 25.95% of the shares respectively, totaling 53.24%, while the third-largest shareholder holds only 0.57% [3] Group 3: Business Overview - *ST Jinbi operates in the maternal and infant consumer goods sector, managing three proprietary brands: LABI BABY, I LOVE BABY, and BABY LABI [3] - The company has faced significant pressure on its performance due to increasing competition in the maternal and infant market [3] Group 4: Financial Performance - Since 2019, *ST Jinbi's revenue has declined from 438 million to 225 million in 2024, with net profits showing losses for three consecutive years from 2022 to 2024 [4] - The company has been under risk warning for delisting due to financial performance issues, as it met criteria for negative profit and revenue thresholds [4] Group 5: Strategic Moves - To mitigate delisting risks, *ST Jinbi has attempted to enter the medical beauty industry, acquiring stakes in Guangdong Hanfei Hospital Investment Co., Ltd. in 2021 and 2023 [5] - In 2025, the company consolidated its medical beauty operations by integrating subsidiaries, but the impact on financial performance has been limited, with a reported revenue of 76.06 million in Q1 2025, a 74.85% increase year-on-year, yet still showing a net loss [5][6]

Group 1: Control Changes in Companies - Recently, several A-share listed companies are undergoing significant control changes, with multiple announcements regarding control rights transfer [1][6] - Honghe Technology (002955) announced on June 4 that its actual controllers are planning a share transfer that may lead to a change in control, with trading partners primarily engaged in investment and asset management [1] - Honghe Technology's stock was suspended from trading starting June 5, with an expected suspension period of no more than two trading days [1] Group 2: Financial Performance of Honghe Technology - In 2024, Honghe Technology reported a revenue of 3.525 billion yuan, a year-on-year decrease of 10.29%, and a net profit attributable to shareholders of 222 million yuan, down 31.20% [1] - In Q1 2025, the company faced further pressure, with revenue of 510 million yuan, a decline of 7.4%, and a net profit of 5.85 million yuan, down 76.7% [1][2] - The company reported a negative cash flow from operating activities of 200 million yuan, a decrease compared to the same period last year [1] Group 3: Market Conditions Affecting Honghe Technology - The decline in Honghe Technology's performance in 2024 was attributed to tightened procurement budgets and intensified competition in the domestic education market [2] - The company is investing in AI technology applications, overseas software products, and new growth products while streamlining teams to reduce costs [2] - Adjustments to the domestic education team and strategic initiatives are expected to lead to a recovery in performance in Q4 2024 and significant growth in Q1 2025 compared to 2024 [2] Group 4: Other Companies Undergoing Control Changes - *ST Jinbi (002762) also announced on June 4 that its controlling shareholders are planning a share transfer, with the specifics yet to be determined [2][3] - *ST Jinbi's stock was suspended from trading starting June 5, with an expected suspension period of no more than two trading days [4] - Anner (002875), known as the "first stock in children's clothing," is also in discussions for a control change, with significant uncertainties remaining [4] Group 5: Recent Transactions and Market Reactions - On June 4, Yiming Pharmaceutical (002826) resumed trading and saw its stock price hit the daily limit, closing at 13.4 yuan per share, with a total market value of 2.6 billion yuan [4] - Yiming Pharmaceutical signed a share transfer agreement with Beijing Fuhai, which plans to acquire 43.8559 million shares, representing 23% of the total shares [4][5] - After the transaction, the controlling shareholder of Yiming Pharmaceutical will change from Gao Fan to Beijing Fuhai, with the actual controller changing to Yao Jinbo, founder of 58.com [5][6]

Core Viewpoint - *ST Jinbi is planning a share transfer involving its controlling shareholders, which has led to a temporary suspension of its stock trading, while the company aims for rapid growth in 2025 to eliminate delisting risks [1][2][3] Group 1: Company Overview - *ST Jinbi focuses on the maternal and infant consumer goods industry, being one of the early entrants in China, with a comprehensive product line covering clothing, cotton products, and various maternal and infant supplies [1] - The company owns three well-known brands: LABI BABY, I LOVE BABY, and BABY LABI, and is currently adjusting its business strategy to integrate maternal and infant products with medical beauty services [1] Group 2: Financial Performance - In 2024, *ST Jinbi reported revenues of 225 million yuan and a net profit of approximately 52.15 million yuan, but a non-recurring net profit loss of about 45.32 million yuan, leading to a warning of potential delisting [1] - The company aims to achieve rapid revenue growth in 2025 through various measures, including expanding its business channels and partnerships, and leveraging AI for sales promotion [2] Group 3: Strategic Initiatives - *ST Jinbi plans to enhance its medical beauty segment and expand its maternal and infant product offerings, with a focus on new product development and innovative sales models [3] - The company has set a target for 2025 to assist its recently acquired subsidiaries, Zhongshan Hanfei and Zhuhai Hanfei, in utilizing AI tools to improve sales management and contribute to overall revenue growth [2][3] - The company reported a 74.8% year-on-year increase in revenue for the first quarter, indicating a positive outlook for sustained growth and the potential to remove the delisting warning [3]